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Background: Pemphigus is frequently diagnosed via indirect immunoﬂuorescence (IIF) or skin biopsy
with direct immunoﬂuorescence staining. However, the accuracy of IIF to detect anti-intercellular sub-
stance autoantibodies (anti-ICS Ab) has not been evaluated in Asian populations.
Method: IIF was performed on 177 patient samples. Demographic data and underlying diseases were
analyzed. Histopathology and direct immunoﬂuorescence results were also reviewed. The false-positive
group included 45 patients without pemphigus but with positive ICS Ab results. The other groups
included true-negative (116 patients without pemphigus and negative ICS Ab results), true-positive (14
pemphigus patients with positive ICS Ab results), and false-negative (two pemphigus patients with
negative ICS Ab results) results. Univariate and multivariate analysis were performed to exam the factors
associated with false positivity.
Results: Anti-ICS Ab detected using IIF has been shown in 87.5% of patients with conﬁrmed pemphigus.
The speciﬁcity of IIF on pemphigus was 72.1%. The positive and negative predictive rates were 23.7% and
98.3%, respectively. The false positive rate was 25.4% (n ¼ 45/177). The titers of the false positive results
were 1:20, 1:40, and 1:80, in 28, 10, and 7 patients, respectively. The false-positive results also dimin-
ished during sequential follow-ups in some patients after treatments. There was higher rates of patients
with blood type O (66.7% vs. 36.3%; p ¼ 0.02) and bullous pemphigoid (31% vs. 15%; p ¼ 0.05) in the false-
positive group, compared with the rest of the population. In the adjusted analysis, blood type O was
found to be signiﬁcantly associated with a false-positive IIF results when compared with blood types A
and B.
Conclusion: This study provided practical statistics for the accuracy of anti-ICS IIF tests. Due to the high
false-positive rate and low positive-predictive rate, the results of anti-ICS IIF for pemphigus diagnosis
should be carefully interpreted.
Copyright © 2016, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Background
Pemphigus is a potentially fatal autoimmune blistering disease
caused by immunoglobulin G (IgG) autoantibodies againsty have no ﬁnancial or non-
atter or materials discussed
y, Wan Fang Hospital, Taipei
ng Road, Taipei 116, Taiwan,
en).
al Association. Published by Elsevidesmoglein (Dsg)3 (a 130-kDa protein) and Dsg1 (a 160-kDa pro-
tein), leading to the destruction of cellecell adhesions between
stratiﬁed keratinocytes.1,2
The diagnosis of pemphigus relies on histological ﬁndings of
intraepidermal acantholysis and immunoﬂuorescence studies
documenting the presence of skin autoantibodies, either via direct
immunoﬂuorescence (DIF) of perilesional skin, indirect immuno-
ﬂuorescence (IIF), or enzyme-linked immunosorbent assay (ELISA)
analysis of patients' sera.3,4 Positive immunoﬂuorescent intercel-
lular substance (ICS) staining is characterized by the deposition of
IgG along the epithelium in a pattern reminiscent of chicken
wire.3,4er Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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available in all medical facilities, and thus, IIF for anti-ICS autoan-
tibodies (anti-ICS Ab) may be the most common clinical test.
However, in clinical practice, the interpretation of both positive and
negative results of this indirect test may be complicated. The
documented sensitivity of anti-ICS IIF in patients with pemphigus
ranges from 81% to 90%,5e8 and the observed variance is because of
the use of substrates such as monkey and guinea pig esoph-
agus.5,6,9,10 In addition, concurrent autoimmune disorders, burns,
infections, and even blood types have been reported to lead to
false-positive test results in a few studies.11e14 Although monkey
esophagus is a common commercial substrate for anti-ICS Ab
screening, the accuracy of this test in Asian populations is currently
unknown. In addition, studies have not thoroughly explored
whether age, sex, concurrent diseases, or other factors, such as
blood type, may interfere with the test results. Furthermore, the
potential of IIF persistence is also unknown. Therefore, this study
investigated the speciﬁcity and sensitivity of anti-ICS and the fac-
tors associated with the accuracy of this diagnostic method.
Materials and methods
Patients
Patients tested for serum anti-ICS Ab with IIF between May 2012
and December 2014 atWan Fang Hospital in Taiwanwere subjected
to a retrospective review. Given the rarity of pemphigus, all the
pemphigus patients in the past decade diagnosed using both IIF and
DIF results were included. Demographics, blood type, laboratory
data, pathology reports, and medical histories of underlying dis-
eases were collected. These patients underwent the tests to conﬁrm
suspicion regarding autoimmune blistering diseases. The diagnosis
of pemphigus or another autoimmune dermatosis was based on
clinical presentation, histologic ﬁndings, IIF and DIF results. Final
diagnoses of other dermatological diseases were based on clinical
manifestations, lab tests, skin biopsy (if available), and the clinical
course with treatment. The false-positive group included 45 pa-
tients without pemphigus but with positive ICS Ab results. The
other groups included true-negative (116 patients without
pemphigus and negative ICS Ab results), true-positive (14
pemphigus patients with positive ICS Ab results), and false-
negative (two pemphigus patients with negative ICS Ab results)
results. The study was approved by the Taipei Medical University-
Joint Institutional Review Board with waiver of informed consent.
IIF study
Patients' sera were collected at Wan Fang Hospital. IIF was per-
formed by incubating serial serum dilutions with a commercial kit
[ImmuGlo™ Anti-Skin Antibody (IC/BMZ) Test System manufac-
tured by IMMCO Diagnostics, Inc.] at the Taipei Institute of Patho-
logyda qualiﬁed laboratory that provides pathology testing
techniques that meet international standards and collaborates as a
referral institute with many hospitals in Taipei. Bound IgG-class
antibodies were detected by incubating monkey esophagus sub-
strate sections with ﬂuorescein-labeled, antihuman IgG. Reactions
were observed under a ﬂuorescence microscope equipped with
appropriate ﬁlters. The presence of anti-ICS Abs was demonstrated
by the appearance of apple-green ﬂuorescence on the respective
histologic structures. The titer was reported as the ﬁnal dilution
(1:20) at which the serum yielded a positive staining pattern.
Data were all conﬁrmed by two professional technicians.
A false-positive result was deﬁned as a positive IIF result for
anti-ICS Ab but a failure of the histo- or immuno-pathological ev-
idence or clinical course to indicate pemphigus rather than otherdiseases. Patients in the “true negative” group had both negative IIF
results and a clear exclusion of pemphigus because of other sug-
gestive diagnoses and a lack of evidence of pemphigus.
Statistics
The summarized statistical results of the baseline characteristics of
all patients are expressed as percentages for categorical data and
means ± standard deviations for continuous variables. Means were
compared using an independent t-test analysis of variance. Cate-
gorical data were assessed using the Chi-square test. Sensitivity,
speciﬁcity, and positive and negative predictive values were also
determined. A multivariate logistic regression was used to assess
the factors associated with false positivity. A p-value of <0.05 was
considered statistically signiﬁcant. PASW Statistics for Windows,
Version 18.0. (Chicago: SPSS Inc. Released 2009) was used for sta-
tistical analysis.
Results
A total of 177 patients, including 101 women (57.1%) and 76 (42.9%)
men were enrolled in the study (Table 1). The mean age was
58.4 ± 21.4 years. The rates of A, B, O, and AB blood types in this
cohort were 26.5%, 25.9%, 44.1%, and 3.3%, respectively. Sixteen
patients were diagnosed with pemphigus [14 pemphigus vulgaris
(PV) and two pemphigus foliaceus (PF)], and 161 patients were
eventually diagnosed with other dermatologic disorders. Fifty-ﬁve
percent of the patients underwent concomitant IIF for the detection
of antibasement membrane zone (anti-BMZ) autoantibodies
indicative of bullous pemphigoid (BP), and 19.2% (34/177) of the
patients were diagnosed with BP. Nonautoimmune-related blis-
tering and spongiotic dermatitis were diagnosed in 67.2% (119/177)
of the patients.
IIF detected anti-ICS Ab in 27.9% (45/161) of the patients without
pemphigus. The false-positive IIF results reported titers of 1:20,
1:40, and 1:80 in 28 (62.2%), 10 (22.2%), and seven (15.6%) patients,
respectively (Table 1). False-negative IIF results were also observed
in two patients diagnosed with PV and PF, respectively. The
sensitivity, speciﬁcity, and positive and negative predictive values
of the IIF test for pemphigus were 87.5% [95% conﬁdence interval
(CI): 61.6e98.5%], 72.1% (95% CI: 64.4e78.8%), 23.7% (95% CI:
13.6e36.6%), and 98.3% (95% CI: 94.1e99.8%) using a standard cut-
off titer of 1:20. These four values were 68.8% (95% CI: 41.3e88.9%),
89.4% (95% CI: 83.6e93.7%), 39.3% (95% CI: 21.5e59.4%), and 96.6%
(95% CI: 92.3e98.9%) with the cut-off point at 1:40. With a cut-off
titer taken at 1:80, the sensitivity decreased to 56.3 (95% CI:
29.9e80.3%) and the rest of the indicants were 95.6% (95% CI:
91.3e98.2%), 56.3% (95% CI: 29.9e80.3%), and 95.7% (95% CI:
91.3e98.2%), respectively.
The persistence of false-positive IIF test results was unknown
according to literature. In our study, four patients had false-positive
ICS staining at a titer of 1:20 (two patients with urticaria and
angioedema, and two with eczema and underlying sicca syn-
drome). Another patient who was eventually diagnosed with
bullous scabies presented with a false-positive staining titer of
1:40, and one patient with eczema and underlying sicca syndrome
presented with a false-positive staining titer of 1:80. The follow-up
IIF test results of these patients were all negative at 3e6 months
after treatment and stabilization of the skin conditions.
The patients were divided into two groups according to their IIF
test results: the “false-positive” group (n ¼ 45) and the “others”
group (n¼ 132). These groups did not differ signiﬁcantly in terms of
the mean age and sex distribution (Table 1). The “false-positive”
group had a signiﬁcantly higher proportion of patients with blood
type O than the “others” group (66.7% vs. 36.3%; p ¼ 0.022). More
Table 1 Baseline demographic and clinical characteristics by false-positivea group and others.b
Variables All (n or %) False positive (n or %) Others (n or %) p
Age 58.4 ± 21.4 62.6 ± 23.3 56.8 ± 20.1 0.15
Sex (female) 101 (57.1) 24 (53.3) 77 (58.3) 0.66
Blood type 0.02
Type A 47 (26.5) 9 (20) 38 (28.8)
Type B 46 (25.9) 5 (11.1) 41 (31.1)
Type AB 6 (3.3) 1 (2.2) 5 (3.7)
Type O 78 (44.1) 30 (66.7) 48 (36.3)
Diagnosis 0.67
Pemphigus vulgaris 14 (7.9) 0 14 (10.6) N/A
Pemphigus foliaceus 2 (1.1) 0 2 (1.5) N/A
Bullous pemphigoid 34 (19.2) 14 (31.1) 20 (15.1) 0.05
Eczema 73 (41.2) 23 (51.1) 50 (37.8) 0.38
Chronic urticaria 14 (7.9) 4 (8.8) 10 (7.6) 0.92
Drug eruption 4 (2.2) 0 4 (3) N/A
Bullous scabies 7 (3.9) 2 (4.4) 5 (3.8) 0.95
Others 29 (16.4) 2 (4.4)c 27 (20.5)d 0.45
Underlying diseases 0.26
Sicca syndrome 14 (7.9) 4 (8.8) 10 (7.5)
Thyroid disease 9 (5.1) 3 (6.7) 6 (4.5)
Behçet's disease 2 (1.1) 0 2 (1.5)
Kidney or liver diseases 45 (25.4) 15 (33.3) 30 (22.7)
Neurologic diseases 34 (19.2) 12 (26.7) 22 (16.7)
Malignancy 7 (3.9) 3 (6.7) 4 (3.0)
Diabetes mellitus 38 (21.5) 12 (26.7) 26 (19.6)
Anti-ICS Ab titers <0.01
Negative 118 (66.7) 0 118 (89.4)
1:20 32 (18.1) 28 (62.2) 4 (2.3)
1:40 27 (15.3) 17 (37.8) 10 (5.6)
Anti-BMZ Ab titers 0.04
Not tested 67 (37.9) 11 (24.4) 56 (42.4)
Negative or 1:20 92 (51.9) 24 (53.3) 68 (51.5)
1:40 18 (10.2) 10 (22.2) 8 (6.1)
Data expressed as mean ± standard deviation or percentage. Comparisons by t-test and Chi-square test.
Anti-ICS Ab ¼ anti-intercellular substance auto-antibody; BMZ ¼ antibasement membrane zone.
a False-positive group included 45 patients without pemphigus but positive ICS Ab
b Others included true-negative (116 patients without pemphigus presenting negative ICS Ab), true-positive (14 pemphigus patients with positive ICS Ab), and false-
negative (two pemphigus patient with negative ICS Ab) groups
c Unclear diagnoses (two)
d Friction blister (two), insect bite reaction (one), polymorphic light eruption (two), fungus infection (one), herpes simplex virus infection (one), oral mucositis (12), vitiligo
(one), alopecia (one), unclear diagnoses (six).
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(31.1% vs. 15.1%; p ¼ 0.055) than in the rest of the population. No
signiﬁcant differences were observed in the proportions of patients
with eczema, urticaria, drug hypersensitivity, bullous scabies, or
other dermatological diseases between the groups (Table 1).
A multivariate logistic regressionwas performed (Table 2). After
adjusting for age, sex, blood type, and BP diagnosis, blood type O
was found to be signiﬁcantly associated with a false-positive IIF
result when comparedwith blood type A [odds ratio (OR), 3.03; 95%Table 2 Factors associated with intercellular cement substance false positivity.a
Risk factors OR (95% CI) p*
constant 0.38
Age (y) 1.04 (0.98e1.06) 0.371
Male 0.77 (0.34e3.19) 0.886
BPb 1.16 (0.54e1.52) 0.437
Blood type
Type O versus Type A 3.03 (1.00e5.37) 0.048
Type O versus Type B 4.06 (1.11e8.96) 0.036
Type O versus Type AB 1.17 (0.82e1.67) 0.394
Anti-BMZ IIF test (1:40)c 2.88 (0.98e8.51) 0.052
Values expressed as odds ratio (95% conﬁdence interval).
* p < 0.05 with signiﬁcant difference.
BMZ ¼ basement membrane zone; BP ¼ bullous pemphigoid; CI ¼ conﬁdence in-
terval; ICS ¼ intercellular cement substance; OR ¼ odds ratio.
a Comparing the “false-positive” group with “others”
b Diagnosis of bullous pemphigoid versus those without bullous pemphigoid
c 1:40 versus negative staining or 1:20.CI: 1.00e5.37) and blood type B (OR, 4.06; 95% CI: 1.11e8.96). A BP
diagnosis was associated with a false-positive anti-ICS IIF test
result. However, a positive anti-BMZ IIF test at a titer 1:40
exhibited a borderline signiﬁcant association (OR, 2.88, 95% CI:
0.98e8.51; p ¼ 0.05) with a false-positive anti-ICS Ab IIF test result
when compared with negative staining or a titer of 1:20 during the
anti-BMZ IIF test.
Discussion
This study demonstrated the accuracy of the anti-ICS IIF test in a
clinical setting. The current study obtained sensitivity, speciﬁcity,
and positive and negative predictive values of 87.5%, 72.1%, 23.7%,
and 98.3%, respectively, for the IIF test for pemphigus. Blood type O
and a higher serum titer of anti-BMZ Ab were associated with a
higher false-positive rate. Although the IIF test remains a useful tool
in clinical practice, the diagnosis of pemphigus should still be made
based on a clinicaleserological correlation.
Previous studies have documented the sensitivity of anti-ICS IIF
testing in patients with pemphigus to be approximately 81e90%,
the current study obtained similar results.5e8 The substrate used in
IIF greatly inﬂuences the sensitivity of this test. Zagorodniuk et al7
reported an IIF test sensitivity of 81% for PV when monkey
esophagus was used as the substrate. Cunha et al8 reported a
sensitivity of 81% for endemic PF when human skinwas used as the
epithelial substrate. Harman et al6,15 reported overall sensitivities
of IIF for pemphigus of 83% with human skin and 90% with monkey
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human skin. Rabbit esophagus has also been used in IIF testing for
pemphigus although this is less common.16 In general, monkey
esophagus, which is rich in Dsg3, is more sensitive for PV antibody
detection.6,15 Guinea pig esophagus and normal human skin, which
are rich in Dsg1, are considered superior substrates for IIF screening
to detect PF antibodies.6,10,15,17
Speciﬁcity, however, has been less frequently discussed in
literature. The speciﬁcity of the IIF test in this study was relatively
low (72%), and false-positive results were achieved for 45 patients.
In clinical practice, IIF is used when considering a diagnosis of
pemphigus, and the interpretation of positive anti-ICS Ab staining
by IIF may be complicated. In our current study, the control par-
ticipants were 161 patients with skin manifestations indicating
suspected autoimmune bullous dermatoses for which pemphigus
had subsequently been excluded as a possible diagnosis, rather
than healthy individuals. Zagorodniuk et al7 compared 50 healthy
people or patients with unrelated skin disorders to 38 pemphigus
patients. In the previous study, the IIF test results were negative for
all 50 controls, indicating a speciﬁcity of 100%. Cunha et al8 also
recruited 15 healthy workers as controls and as expected, failed to
detect anti-ICS Ab using IIF in these individuals. However, Ahmed
and Workman11 reported that 14 of 1500 patients (0.9%) subjected
to IIF serum analysis had false-positive intercellular IgG deposition
results. In our study, 45 of the 177 patients (25.4%) had false-
positive resultsda much higher rate than previously reported.
The speciﬁcity of this test was also less favorable.
Among the patients with false-positive anti-ICS IIF test results,
31.1% were diagnosed with BP. In previous reports, false-positive
anti-ICS Ab results were mostly observed in patients with other
autoimmune disorders associated with the potential production of
pemphigus-like autoantibodies including BP, cicatricial pemphi-
goid, epidermolysis bullosa acquisita, and systemic lupus erythe-
matosus.11,12,14,18 In addition, epidermal antigens might be released
by burns, extensive scratching, infections, and biochemical insults
(e.g., drugs) that cause the exposure of antigens to the immune
system and subsequently induce anti-ICS Ab production.11,13,19
Therefore, the presence of these antibodies might be transient
and undetectable after skin recovery, as observed in our patients
with negative follow-up results after initial positive results.
The most common blood type in our cohort was O (44.1%), fol-
lowed by A (26.5%), B (25.9%), and AB (3.3%). This distribution was
compatible with the frequencies of blood types A, B, O, and AB
among general blood donors as 26.7%, 23.8%, 43.6%, and 5.9% from
the Taiwan Blood Services Foundation, which differed from the
distribution in other racial/ethnic populations.20 In the adjusted
analysis, blood type O was associated with a higher rate of false-
positive IIF results than blood types A and B were. This ﬁnding
might be attributable to cross-reactivity between blood-group
antigen-speciﬁc antibodies and the ICS.21 IgM, IgG, or IgA class
antibodies may be directed against the human A and B blood group
antigens. Some sera contain all three classes, and although non-
stimulated individuals are predominantly IgM, isotype switching to
IgG may occur due to genetic and environmental factors.22,23 An
encounter between blood group antibodies and their antigenic
targets on primate-derived substrates could lead to a pemphigus-
like test pattern. However, differences between pemphigus-
related and group A/B red-cell antibody-related staining patterns
have been reported.24,25 Anti-A and anti-B IgG iso-antibody-related
staining tends to spare the intercellular spaces of the basal layer
and thus yields a coarser appearance, whereas true-positive
staining tends to be sharper and more deﬁned.24,25 This effect
could be abolished via absorption with puriﬁed A and B antigens in
solution.11 Similar ﬁndings were reported in some patients with
symptoms of sicca but no other autoimmune features.26 In aprevious study, 12 of 13 patients whose sera exhibited antisalivary
duct autoantibody-like staining had the O blood type.26 In that
study, ductal-pattern staining was abolished after absorption with
blood group AB erythrocytes or antigens.26 Isotype-switched IgG
AB blood group antibodies might cross-react not only with primate
epithelial ICS, but also with salivary ducts, leading to false-positive
test results.
In addition, a high frequency of immune ABO antibodies (69%)
has been reported in group O Thai blood donors.27 Moreover, a high
frequency of IgG anti-A and anti-B hemolysins was reported in
Asian and African-American populations, relative to that in Cau-
casians.22 This discrepancy might also explain the higher rate of
false-positivity in the present Taiwanese cohort. However, data
from a blood transplant donor population indicated that only 13%
had high anti-A or -B Ab titers (>100).28 This ﬁnding might explain
why false-positive anti-ICS IIF test results were not obtained for all
patients with blood type O.
As this study involved an observational cohort, our ability to
elucidate deﬁnite links was limited. Despite the rather limited
sample size, the ﬁndings corresponded to the generally low inci-
dence of pemphigus and reﬂected the diagnostic challenge
encountered in daily practice. In addition, an ELISA was not per-
formed due to its unavailability in the clinical laboratory. Further-
more, selection bias might exist with regard to the fact that patients
underwent testing based on a physician's clinical judgment. How-
ever, the study design was based on a common clinical setting. The
patients were recruited at a single center, which comprises another
limitation and might lead to a suspicion that the high false-positive
rate was related to laboratory bias at this center. However, sera
from the patients were sent to the Taipei Institute of Pathology, an
institute that uses the same commercial kits, standard techniques,
and professional technicians to process anti-ICS IIF tests referred
from several hospitals in Taipei.Conclusion
This study provided a practical statistical analysis of anti-ICS IIF test
for the diagnosis of pemphigus. The IIF test for the detection of anti-
ICS Ab could be used as a complementary serologic diagnostic test
for pemphigus as it yielded favorable sensitivity. However, the
speciﬁcity of the test remains unsatisfactory, as demonstrated by
the high false-positive rate. Careful interpretation of the test results
is essential, especially in patients with the O blood type. In addition
to the IIF test, the clinical presentation and histo- and immuno-
pathological ﬁndings are still required for the diagnosis of
pemphigus or to suggest other dermatological diseases.References
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